| hydroxychloroquine | inhibit | SARS-CoV-2 (count: 2) | |
|---|---|
| Very recently, a Chinese team published results of a study demonstrating that chloroquine and hydroxychloroquine inhibit SARS-CoV-2 in vitro with hydroxychloroquine (EC50=0.72%µM) found to be more potent than chloroquine (EC50=5.47%µM) [14] .
-- reference not found! | |
| These results are of great importance because a recent paper has shown that the mean duration of viral shedding in patients suffering from COVID-19 in China was 20 days (even 37 days for the longest duration) [19] Very recently, a Chinese team published results of a study demonstrating that chloroquine and hydroxychloroquine inhibit SARS-CoV-2 in vitro with hydroxychloroquine (EC50=0.72%µM) found to be more potent than chloroquine (EC50=5.47%µM) [14] .
-- reference not found! | |
| hydroxychloroquine | clearing | nasopharyngeal carriage of SARS-CoV-2 (count: 1) | |
| We show here that hydroxychloroquine is efficient in clearing viral nasopharyngeal carriage of SARS-CoV-2 in COVID-19 patients in only three to six days, in most patients.
-- reference not found! | |
| COVID-19 patients | be treated with | hydroxychloroquine (count: 1) | |
| We therefore recommend that COVID-19 patients be treated with hydroxychloroquine and azithromycin to cure their infection and to limit the transmission of the virus to other people in order to curb the spread of COVID-19 in the world.
-- reference not found! | |
| Percentage | is in | COVID-19 patients treated with hydroxychloroquine (count: 1) | |
| Percentage of patients with PCR-positive nasopharyngeal samples from inclusion to day6 post-inclusion in COVID-19 patients treated with hydroxychloroquine only, in COVID-19 patients treated with hydroxychloroquine and azithomycin combination, and in COVID-19 control patients.
-- reference not found! | |
| hydroxychloroquine treatment | is associated with | load reduction/disappearance in COVID-19 patients (count: 1) | |
| Despite its small sample size our survey shows that hydroxychloroquine treatment is significantly associated with viral load reduction/disappearance in COVID-19 patients and its effect is reinforced by azithromycin.
-- reference not found! | |